1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. SciClone Pharmaceuticals (Holdings) Limited
  6. News
  7. All News
    6600   KYG4271B1023

SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

(6600)
  Report
Delayed Hong Kong Stock Exchange  -  05/17 04:08:55 am EDT
8.720 HKD   +2.83%
04/19China Accepts SciClone Pharma's Clinical Trial Application for Neuroblastoma Immunotherapy
MT
03/29SciClone Pharmaceuticals Limited commences an Equity Buyback Plan for 67,787,426 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2021.
CI
03/25SciClone Pharma's Per-Share Earnings Slip in 2021
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
04/19China Accepts SciClone Pharma's Clinical Trial Application for Neuroblastoma Immunother..
MT
03/29SciClone Pharmaceuticals Limited commences an Equity Buyback Plan for 67,787,426 shares..
CI
03/25SciClone Pharma's Per-Share Earnings Slip in 2021
MT
03/24SciClone Pharma Launches Buyback Program; Shares Rally 14%
MT
03/24SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended Decem..
CI
03/24Sciclone Pharmaceuticals Limited Recommends Final Dividend for the Year Ended December ..
CI
02/24SciClone Pharma Sees Higher Profit in 2021
MT
2021SciClone Pharmaceuticals Grants Nearly 4 Million Share Options
MT
2021SCICLONE PHARMACEUTICALS LIMITED(SEH : 6600) added to S&P Global BMI Index
CI
2021SCICLONE PHARMACEUTICALS : Wins License for Preclinical Miniature Solid Tumor Inhibitor
MT
2021Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA (naxitamab-gqgk) in..
AQ
2021SCICLONE PHARMACEUTICALS : Gets Priority Review for Neuroblastoma Treatment in China
MT
2021NMPA Grants Priority Review to BLA of DANYELZA«
CI
2021610,329,800 Ordinary Shares of SciClone Pharmaceuticals Limited are subject to a Lock-U..
CI
2021Sciclone Pharmaceuticals Limited Announces Unaudited Consolidated Financial Results for..
CI
2021ThinkGeek Network Technology Files for Hong Kong IPO
MT
2021Beijing Evercare Medical Files for Hong Kong IPO
MT
2021SCICLONE PHARMACEUTICALS : China Accepts SciClone Pharma's Biologics License Application f..
MT
2021SciClone Pharmaceuticals Announces NMPA Acceptance of BLA of DANYELZA (naxitamab-gqgk)
CI
2021Y MABS THERAPEUTICS : mAbs Announces NMPA Submission of BLA for DANELZA (naxitamab-gqgk) i..
AQ
2021SciClone Pharmaceuticals Limited submits the Biologics License Application for DANYELZA..
CI
2021MARKET CHATTER : Medlive Technology Passes Hong Kong Listing Hearing
MT
2021SciClone Pharmaceuticals Limited Appoints Wang Haixia as Non-Executive Director
CI
2021MARKET CHATTER : US-Based Biohaven Pharma Mulls Spinoff, Separate Listing of APAC Business..
MT
2021MARKET CHATTER : China's Neusoft Medical Files for Hong Kong IPO
MT
2021SCICLONE PHARMACEUTICALS : Form of proxy for the annual general meeting to be held on wedn..
PU
2021SCICLONE PHARMACEUTICALS : Proposed election and re-election of directors and proposed gra..
PU
2021MARKET CHATTER : China's Clover Biopharmaceuticals Files for Hong Kong IPO
MT
2021SCICLONE PHARMACEUTICALS : Pharmaceutical Begins Clinical Study for COVID-19 Inactivated V..
MT
2021SCICLONE PHARMACEUTICALS : Pharma tests hepatitis drug as COVID-19 vaccine enhancer
RE
2021SCICLONE PHARMACEUTICALS : Voluntary Announcement - Official Initiation of the Clinical St..
PU
2021SCICLONE PHARMACEUTICALS : Pharma Officially Begins Cooperation with Shanghai SF Pharmaceu..
MT
2021SCICLONE PHARMACEUTICALS : Voluntary Announcement - Formation of the Strategic Cooperation..
PU
2021ScicCone Pharmaceuticals Limited Announces Formation of the Strategic Cooperation with ..
CI
2021SCICLONE PHARMACEUTICALS : Pharma's Hong Kong IPO Stabilization Period Ends Without Overal..
MT
2021SCICLONE PHARMACEUTICALS : End of stabilization period, stabilization actions and lapse of..
PU
2021Sciclone Pharmaceuticals Limited Announces Audited Consolidated Earnings Results for th..
CI
2021MARKET CHATTER : Carlyle-Backed Abbisko Therapeutics Eyes $250 Million in Hong Kong IPO
MT
2021SciClone Pharmaceuticals Limited has completed an IPO in the amount of HKD 2.180509 bil..
CI
2021SciClone Pharmaceuticals Limited has filed an IPO in the amount of HKD 2.180509 billion..
CI
2020Ability Pharmaceuticals, S.L. announced that it expects to receive Ç2.46 million in fun..
CI
2020EpicentRx, Inc. announced that it expects to receive funding from SciClone Pharmaceutic..
CI
2017SCICLONE PHARMACEUTICALS, INC.(NASDA : SCLN) dropped from Russell 3000 Index
CI
2017SCICLONE PHARMACEUTICALS, INC.(NASDA : SCLN) dropped from Russell 2000 Index
CI
2017SCICLONE PHARMACEUTICALS, INC.(NASDA : SCLN) dropped from S&P 600
CI
2017SCICLONE PHARMACEUTICALS, INC.(NASDA : SCLN) dropped from S&P 1000
CI
2017SCICLONE PHARMACEUTICALS, INC.(NASDA : SCLN) dropped from S&P Global BMI Index
CI
2017SCICLONE PHARMACEUTICALS, INC.(NASDA : SCLN) dropped from S&P 600 Health Care
CI
2017SCICLONE PHARMACEUTICALS, INC.(NASDA : SCLN) dropped from S&P Pharmaceuticals Select Indus..
CI
2017SCICLONE PHARMACEUTICALS, INC.(NASDA : SCLN) dropped from S&P TMI Index
CI
2017SCICLONE PHARMACEUTICALS, INC.(NASDA : SCLN) dropped from S&P Composite 1500
CI
2017SciClone Pharmaceuticals, Inc. Announces Board Changes
CI
2017SCICLONE PHARMACEUTICALS, INC.(NASDA : SCLN) dropped from NASDAQ Composite Index
CI
2017Consortium of GL Trade Investment Limited, Avengers Limited, Ascendent Capital Partners..
CI
2017SciClone Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for th..
CI
2017SCICLONE PHARMACEUTICALS, INC.(NASDA : SCLN) added to Russell 2000 Value-Defensive Index
CI
2017SciClone Pharmaceuticals, Inc. Announces Election of Directors
CI
2017TRANSCRIPT : SciClone Pharmaceuticals, Inc., Q1 2017 Earnings Call, May 10, 2017
CI
2017SciClone Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the ..
CI
2017SciClone Seeks Acquisitions
CI
2017TRANSCRIPT : SciClone Pharmaceuticals, Inc., Q4 2016 Earnings Call, Mar 06, 2017
CI
2017SciClone Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the ..
CI
2017Sciclone Pharmaceuticals, Inc. Announces Resignation of Robert King, Senior Vice Presid..
CI
2016SCICLONE PHARMACEUTICALS, INC.(NASDA : SCLN) dropped from NASDAQ Biotechnology Index
CI
2016SciClone Pharmaceuticals Reports Earnings Results for the Third Quarter Ended September..
CI
2016Consortium of Ally Bridge Lb Healthcare Master Fund Ltd of Ally Bridge Group, GL China ..
CI
2016TRANSCRIPT : SciClone Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 09, 2016
CI
2016SciClone Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for th..
CI
2016SciClone Pharmaceuticals, Inc. appoints Carey Chern as General Counsel
CI
2016TRANSCRIPT : SciClone Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 09, 2016
CI
2016SciClone Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for th..
CI
2016Sciclone Pharmaceuticals, Inc. Announces Resignation of Charles Meng as General Counsel..
CI
2016SciClone Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year 2016
CI
2016SciClone Provides Update On Strategic Review
CI
2016Ability Pharmaceuticals Enters into Licensing Agreement with SciClone Pharmaceuticals, ..
CI
1  2  3Next